Trial Profile
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Patients Failed in First-line Chemotherapy: A Phase II Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 30 Jan 2023 Status changed from suspended to discontinued.
- 16 Mar 2021 Planned End Date changed from 30 Jun 2020 to 31 Dec 2022.
- 16 Mar 2021 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2022.